Archaea comprise a unique domain of organisms with distinct biochemical and genetic differences from bacteria. Methane-forming archaea, methanogens, constitute the predominant group of archaea in the human gut microbiota, with Methanobrevibacter smithii being the most prevalent. However, the effect of methanogenic archaea and their methane production on chronic disease remains controversial. As perturbation of the microbiota is a feature of chronic conditions, such as cardiovascular disease, neurodegenerative diseases and chronic kidney disease, assessing the influence of archaea could provide a new clue to mitigating adverse effects associated with dysbiosis. In this review, we will discuss the putative role of archaea in the gut microbiota in humans and the possible link to chronic diseases.
|Original language||English (US)|
|State||Published - Aug 17 2022|
Bibliographical noteKAUST Repository Item: Exported on 2022-09-14
Acknowledged KAUST grant number(s): BAS/1/1096-01-01
Acknowledgements: Conselho Nacional de Pesquisa (CNPq) and Coordenação de Aperfeiçoamento de Pessoal deNível Superior (CAPES), Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ) support Denise Mafra research. ASR and JS were supported by KAUST grant KAUST (BAS/1/1096-01-01).
ASJC Scopus subject areas
- Infectious Diseases